CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Compass Therapeutics Reports New PD-1 Cleavage Mechanism for CTX-10726 in Preclinical Studies

By Public Technologies
  • Compass Therapeutics will present preclinical CTX-10726 findings at the Society for Immunotherapy of Cancer annual meeting on November 7, 2026.
  • The bispecific antibody removed PD-1 receptors from T cells only when VEGF-A was present, suggesting targeted activity in the tumor microenvironment.
  • Combining CTX-10726 with CTX-471 inhibited tumor growth more than either treatment alone in checkpoint inhibitor-resistant mouse models.
  • An ongoing Phase 1 dose-escalation trial is enrolling patients with advanced solid tumors whose standard treatments, including checkpoint inhibitors, have failed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060900PRIMZONEFULLFEED9871752) on November 06, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.